The Essential Blood Panel for Men Optimizing Longevity

Most men get an annual blood test that checks a handful of basic markers, receive a cursory "everything looks normal," and move on. This approach misses critical information about aging processes unfolding silently in your body.

If you're serious about longevity, your blood panel should be comprehensive, intentional, and interpreted with an eye toward optimal ranges—not just the pathological cutoffs that distinguish disease from "normal." This article maps the biomarkers that matter, what they tell you about your trajectory, and how often you should measure them.

The Comprehensive Metabolic Panel: Foundation Markers

Your standard comprehensive metabolic panel (CMP) checks 14 basic markers: glucose, electrolytes, kidney function, liver function, and blood protein. These are necessary but insufficient for longevity optimization.

Fasting Glucose: This single-point measurement tells you little. A fasting glucose of 95 mg/dL is "normal" by standard ranges but signals early metabolic dysfunction. Optimal range for longevity: below 90 mg/dL, ideally 75-85 mg/dL.

Kidney Function (Creatinine and eGFR): Declining kidney function is a robust predictor of mortality independent of other risk factors. The Framingham Heart Study has repeatedly shown that even modest declines in glomerular filtration rate (eGFR) correlate with cardiovascular disease and all-cause mortality. Check baseline values in your 30s to establish your trajectory. Optimal eGFR: 60+ mL/min/1.73m² (it declines naturally with age, but the slope matters). For men, a creatinine under 1.0 mg/dL is preferable; above 1.1 mg/dL warrants investigation.

Liver Function (AST, ALT, GGT): Elevated liver enzymes suggest fatty liver disease, which is rampant and usually silent. Non-alcoholic fatty liver disease (NAFLD) predicts cardiovascular disease, metabolic dysfunction, and increased mortality. Optimal: AST and ALT both under 30 U/L (many labs use 40 as the upper limit—don't rely on that). Elevated GGT independently predicts mortality and is a marker of oxidative stress; keep it under 50 U/L.

The Lipid Panel: Beyond Total Cholesterol

The traditional lipid panel—total cholesterol, LDL, HDL, triglycerides—is outdated for serious longevity work. What matters far more is particle size and count, particularly apolipoprotein B (ApoB).

ApoB is the Superior Marker: ApoB represents the actual number of atherogenic particles in your blood. This matters more than LDL-cholesterol, because two people with identical LDL-C can have vastly different particle counts. Peter Attia, physician and longevity researcher, has made ApoB central to his biomarker strategy because it's a stronger predictor of cardiovascular disease risk than traditional lipids.

Optimal ApoB: under 70 mg/dL (some researchers argue for under 60 mg/dL for optimal longevity). If your ApoB is elevated despite normal LDL-C, you have a discordant lipid pattern that signals higher risk.

HDL Cholesterol: Higher is better, but the absolute number is less important than the ratio. Optimal: above 50 mg/dL, ideally 60+.

Triglycerides: These reflect carbohydrate metabolism and systemic inflammation. Elevated triglycerides (above 100 mg/dL fasting) predict cardiovascular disease and metabolic dysfunction. Optimal: under 70 mg/dL. A triglyceride-to-HDL ratio above 2:1 suggests insulin resistance.

Lipoprotein(a) [Lp(a)]: This is a genetically determined particle that dramatically increases cardiovascular risk and is largely overlooked in routine screening. It's not modifiable through diet or exercise—it's determined by genetics—but knowing your level informs your overall risk calculation and may influence treatment decisions. Optimal: under 50 nmol/L (some experts argue for under 30 nmol/L).

Metabolic Health: Insulin and Glucose Dynamics

This is where the rubber meets the road for longevity. Most cardiovascular disease, dementia, and metabolic disease begins with insulin resistance.

Fasting Insulin: This is dramatically underutilized. A fasting insulin under 5 mIU/L suggests good metabolic health; above 10 mIU/L signals insulin resistance. Many men have fasting glucose in the "normal" range with elevated fasting insulin—this is the danger zone. Optimal: 2-4 mIU/L.

HOMA-IR (Homeostatic Model Assessment for Insulin Resistance): This calculation (fasting glucose × fasting insulin / 405) quantifies insulin resistance. HOMA-IR below 1.0 is optimal; above 2.0 indicates significant insulin resistance. This single metric predicts diabetes onset, cardiovascular disease, and mortality.

HbA1c (Glycated Hemoglobin): This three-month average of blood glucose is far more informative than a single fasting reading. Standard cutoffs are: normal under 5.7%, prediabetic 5.7-6.4%, diabetic 6.5%+. For longevity, aim for HbA1c under 5.5%—ideally 5.0-5.3%. Even HbA1c in the 5.6-5.7% range predicts increased mortality.

Reproductive Hormones and Metabolic Health

Testosterone is far more than a virility marker; it's central to metabolic health, bone density, muscle mass, and cardiovascular function in men. The relationship is complex—both low and extremely high testosterone correlate with mortality risk, but most men in modern environments lean toward insufficiency.

Total Testosterone: This should be measured on a fasting morning sample (testosterone is lowest in afternoon). Optimal range for men: 500-800 ng/dL. Below 400 ng/dL warrants investigation; above 1200 ng/dL suggests exogenous hormone use or unusual physiology.

Free Testosterone: Only 1-2% of testosterone is unbound; most is bound to SHBG (see below). Free testosterone better correlates with physiological effects. Optimal: 9-30 pg/mL depending on assay.

Sex Hormone-Binding Globulin (SHBG): This protein regulates testosterone bioavailability and inversely correlates with insulin—higher SHBG means lower free testosterone, and SHBG increases with good metabolic health. Optimal SHBG: 35-50 nmol/L. If your SHBG is low (below 25), suspect insulin resistance.

Inflammatory Markers

Chronic inflammation is the silent accelerant of aging. High-sensitivity C-reactive protein (hsCRP) and homocysteine are two critical markers often missing from routine panels.

hsCRP (High-Sensitivity C-Reactive Protein): This measures inflammation and independently predicts cardiovascular disease, mortality, and cognitive decline. Standard labs often don't use the high-sensitivity version; insist on hsCRP. Optimal: below 1.0 mg/L, ideally under 0.5 mg/L. Above 3.0 mg/L indicates elevated cardiovascular risk.

Homocysteine: An elevated amino acid that damages the endothelium and predicts cardiovascular disease and cognitive decline. The Framingham Heart Study and other prospective cohorts show homocysteine above 13 μmol/L correlates with increased mortality. Optimal: under 10 μmol/L. If elevated, supplementation with B6, B12, and folate can usually reduce it.

Nutrient Status and Thyroid Function

Vitamin D (25-hydroxyvitamin D): This isn't just a bone marker—vitamin D regulates immune function, cell proliferation, and is associated with cardiovascular health, cancer risk, and all-cause mortality. Optimal: 40-60 ng/mL (100-150 nmol/L). Below 30 ng/mL is deficient; above 100 ng/mL may offer diminishing returns. Most men benefit from supplementation of 2000-4000 IU daily to maintain optimal levels.

Complete Blood Count (CBC) with Differential: Baseline and periodically checks red and white blood cell counts and hemoglobin. Declining hemoglobin below 14 g/dL can impair oxygen delivery; elevated white blood cell count suggests chronic infection or inflammation. A low lymphocyte percentage (under 20%) may indicate immune dysregulation.

Thyroid Panel: TSH, free T3, and free T4. TSH of 2-4 mIU/L is often considered "normal" but men with TSH above 2.5 have more symptoms and worse metabolic health. Optimal TSH: 1-2.5 mIU/L. Free T4 and free T3 should be in the upper half of normal ranges; if TSH is rising with declining free T3, suspect early thyroid dysfunction (often subclinical hypothyroidism).

Testing Frequency and Longitudinal Tracking

Testing should be strategic and longitudinal—the trajectory matters as much as the absolute value.

Ages 30-40 (Baseline Decade): Establish baseline measurements of all markers above. Even if values are "normal," baseline comparison allows you to track your personal trajectory. Annual testing for glucose, lipids, CMP.

Ages 40-50: Annual lipid panel with ApoB, metabolic markers (fasting glucose, insulin, HOMA-IR, HbA1c), inflammatory markers (hsCRP). Every 2-3 years: comprehensive panel including thyroid, vitamin D, homocysteine.

Ages 50+: Annual comprehensive panel. Every 5 years or when symptomatic: advanced lipid testing, lipoprotein(a), inflammatory markers. Quarterly or semi-annual testing if on interventions (statins, lifestyle changes) to track efficacy.

Optimal Ranges vs. Normal Ranges

This is crucial: "normal" range (the 95% reference interval) is not optimal for longevity. A value can be statistically normal while still predicting disease and shortened lifespan. Use the ranges outlined in this article as your targets, not your labs' reference intervals.

Practical Protocol

1. Find a proactive physician or functional medicine practitioner who will order these tests and interpret them through a longevity lens, not just screen for disease.
2. Track longitudinally: Request copies of all blood work. Build a spreadsheet to track values over years.
3. Order comprehensive tests annually if you're serious about optimization. This typically costs $200-400 out of pocket; prevention is cheaper than disease management.
4. Act on abnormal markers: If insulin resistance appears, prioritize metabolic interventions (strength training, time-restricted eating, reduced refined carbohydrates). If inflammation is elevated, investigate underlying causes. If lipids are discordant, consider pharmacological intervention.

Your blood panel is a map of your internal aging process. Make it comprehensive, measure it consistently, and use it to guide interventions before disease appears. This is how you shift from reactive medicine to true prevention.

---

References:

• Framingham Heart Study longitudinal cohort analyses on lipids, kidney function, and mortality
• Peter Attia, "Outlive" (2023) and blog at peterattia.com on biomarker optimization
• Levey et al., 2009, on eGFR and mortality prediction
• Sabatine et al., 2010, NEJM study on ApoB as superior to LDL-C
• Finnish Diabetes Prevention Study and subsequent HOMA-IR validation studies